{"id":67885,"date":"2024-04-30T10:54:39","date_gmt":"2024-04-30T08:54:39","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=67885"},"modified":"2024-04-30T10:55:50","modified_gmt":"2024-04-30T08:55:50","slug":"msd-joins-the-open-targets-consortium","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/","title":{"rendered":"MSD joins the Open Targets consortium"},"content":{"rendered":"\n<p>Open Targets, a public-private partnership dedicated to pre-competitive drug discovery research, today announced MSD, the tradename of Merck &amp; Co., Inc., Rahway, N.J., USA, as the latest partner to join the consortium. Open Targets aims to accelerate the development of safe and effective medicines by leveraging cutting-edge technologies to identify, prioritise, and validate potential drug targets. MSD\u2019s expertise in drug discovery will complement the strengths of the current partners: EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Sanofi, Pfizer, and Genentech, a member of the Roche group.&nbsp;<\/p>\n\n\n\n<p>Open Targets was founded in 2014 to help address the high attrition rates of potential new therapies in clinical trials. Retrospective analyses \u2013 <a href=\"https:\/\/www.nature.com\/articles\/d41573-023-00158-x\">including from Open Targets<\/a> \u2013 show that clinical trials are more likely to succeed when the link between the disease and the drug target is supported by evidence from genetics and genomics studies. The consortium bridges the gap between academic research and pharmaceutical drug development to generate and interpret the evidence that supports decision making in drug target discovery.&nbsp;<\/p>\n\n\n\n<p>Open Targets partners collaborate on innovative projects aiming to identify causal links between targets, biological pathways, and disease. The consortium\u2019s research portfolio combines systematic, large-scale experimental techniques with cutting-edge informatics approaches and addresses all aspects of human health and disease, with a particular focus on immunology and inflammation, oncology, and neurodegeneration.&nbsp;<\/p>\n\n\n\n<p>\u201cMSD is a fantastic addition to the partnership,\u201d said David Hulcoop, Executive Director of Open Targets. \u201cEvery new partner pushes the consortium forward and enables us to aim for more ambitious and impactful projects. With MSD\u2019s reputation for scientific excellence, I\u2019m excited to see what we can achieve together.\u201d&nbsp;<\/p>\n\n\n\n<p>The partnership is committed to rapid publication to openly share experimental data, informatic methods, and other knowledge generated by the consortium with the broader scientific community. In the 10 years since the partnership was founded, Open Targets has published research that provides evidence of novel target-disease associations and creates or extends data infrastructures that are foundational to the identification and prioritisation of potential drug targets.&nbsp;<\/p>\n\n\n\n<p>\u00a0\u201cWe are pleased to join the Open Targets consortium and believe this unique public-private model will allow us to leverage large-scale genomics data along with advances in AI and machine learning, so we can better understand the underlying drivers of disease and enable more efficient target discovery,\u201d said Iya Khalil, Vice President and Head of Data, AI and genome sciences, MSD Research Laboratories. \u201cWe look forward to working closely with our partners at Open Targets.\u201d\u00a0<\/p>\n\n\n\n<p>This press release was originally <a href=\"https:\/\/www.opentargets.org\/news\/msd-joins-Open-Targets-Apr-2024.html\">published on the Open Targets website<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative\u2019s collaborative efforts in drug discovery.<\/p>\n","protected":false},"author":122,"featured_media":54172,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[11052,17597],"tags":[28,312,36,42,763],"embl_taxonomy":[2906,11100],"class_list":["post-67885","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-announcements","category-embl-announcements","tag-bioinformatics","tag-drug-discovery","tag-embl-ebi","tag-genomics","tag-open-targets","embl_taxonomy-embl-ebi","embl_taxonomy-open-targets"],"acf":{"featured":true,"show_featured_image":false,"field_target_display":"both","field_article_language":{"value":"english","label":"English"},"article_intro":"<p>MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative\u2019s collaborative efforts in drug discovery<\/p>\n","related_links":false,"source_article":false,"in_this_article":false,"press_contact":"None","article_translations":false,"languages":""},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"b14d3f13-5670-44fb-8970-e54dfd9c921a\";i:1;s:36:\"89e00fee-87f4-482e-a801-4c3548bb6a58\";i:2;s:36:\"a99d1a7c-ca83-4c00-ab61-d082d3e41ce3\";}","parents":[],"name":["EMBL-EBI"],"slug":"embl-ebi","description":"Where &gt; All EMBL sites &gt; EMBL-EBI"},{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"18699e63-ed43-40c6-8d1c-203db7ed72ee\";i:2;s:36:\"418846e9-61d5-456f-a171-9ec5018d2a02\";}","parents":[],"name":["Open Targets"],"slug":"open-targets","description":"What &gt; EMBL-EBI Services &gt; Open Targets"}],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MSD joins the Open Targets consortium | EMBL<\/title>\n<meta name=\"description\" content=\"MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative\u2019s collaborative efforts in drug discovery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD joins the Open Targets consortium | EMBL\" \/>\n<meta property=\"og:description\" content=\"MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative\u2019s collaborative efforts in drug discovery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-30T08:54:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-30T08:55:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Helena Cornu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Helena Cornu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/\"},\"author\":{\"name\":\"Helena Cornu\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/28025546c614d54b4274ff601f5e37b0\"},\"headline\":\"MSD joins the Open Targets consortium\",\"datePublished\":\"2024-04-30T08:54:39+00:00\",\"dateModified\":\"2024-04-30T08:55:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/\"},\"wordCount\":435,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\",\"keywords\":[\"bioinformatics\",\"drug discovery\",\"embl-ebi\",\"genomics\",\"open targets\"],\"articleSection\":[\"Announcements\",\"EMBL Announcements\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/\",\"url\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/\",\"name\":\"MSD joins the Open Targets consortium | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\",\"datePublished\":\"2024-04-30T08:54:39+00:00\",\"dateModified\":\"2024-04-30T08:55:50+00:00\",\"description\":\"MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative\u2019s collaborative efforts in drug discovery.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\",\"width\":1000,\"height\":600,\"caption\":\"Open Targets. Credit: Karen Arnott\/EMBL-EBI\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/28025546c614d54b4274ff601f5e37b0\",\"name\":\"Helena Cornu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/eff3a8ffe7da00a022e3fead24b6197e417a8b3db2e3db577e75e5fd39ac9701?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/eff3a8ffe7da00a022e3fead24b6197e417a8b3db2e3db577e75e5fd39ac9701?s=96&d=mm&r=g\",\"caption\":\"Helena Cornu\"},\"url\":\"https:\/\/www.embl.org\/news\/author\/hcornu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MSD joins the Open Targets consortium | EMBL","description":"MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative\u2019s collaborative efforts in drug discovery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/","og_locale":"en_US","og_type":"article","og_title":"MSD joins the Open Targets consortium | EMBL","og_description":"MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative\u2019s collaborative efforts in drug discovery.","og_url":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2024-04-30T08:54:39+00:00","article_modified_time":"2024-04-30T08:55:50+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","type":"image\/jpeg"}],"author":"Helena Cornu","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Helena Cornu","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/"},"author":{"name":"Helena Cornu","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/28025546c614d54b4274ff601f5e37b0"},"headline":"MSD joins the Open Targets consortium","datePublished":"2024-04-30T08:54:39+00:00","dateModified":"2024-04-30T08:55:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/"},"wordCount":435,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","keywords":["bioinformatics","drug discovery","embl-ebi","genomics","open targets"],"articleSection":["Announcements","EMBL Announcements"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/","url":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/","name":"MSD joins the Open Targets consortium | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","datePublished":"2024-04-30T08:54:39+00:00","dateModified":"2024-04-30T08:55:50+00:00","description":"MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative\u2019s collaborative efforts in drug discovery.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/embl-announcements\/msd-joins-the-open-targets-consortium\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","width":1000,"height":600,"caption":"Open Targets. Credit: Karen Arnott\/EMBL-EBI"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/28025546c614d54b4274ff601f5e37b0","name":"Helena Cornu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/eff3a8ffe7da00a022e3fead24b6197e417a8b3db2e3db577e75e5fd39ac9701?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eff3a8ffe7da00a022e3fead24b6197e417a8b3db2e3db577e75e5fd39ac9701?s=96&d=mm&r=g","caption":"Helena Cornu"},"url":"https:\/\/www.embl.org\/news\/author\/hcornu\/"}]}},"field_target_display":"both","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/67885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/122"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=67885"}],"version-history":[{"count":2,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/67885\/revisions"}],"predecessor-version":[{"id":67925,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/67885\/revisions\/67925"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/54172"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=67885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=67885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=67885"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=67885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}